Metacognition Is Uniquely Related to Concurrent and Prospective Assessments of Negative Symptoms Independent of Verbal Memory in Serious Mental Illness.
Journal
The Journal of nervous and mental disease
ISSN: 1539-736X
Titre abrégé: J Nerv Ment Dis
Pays: United States
ID NLM: 0375402
Informations de publication
Date de publication:
11 2020
11 2020
Historique:
pubmed:
3
8
2020
medline:
7
4
2021
entrez:
3
8
2020
Statut:
ppublish
Résumé
The inability to synthesize information into experience of self and others could be one significant cause of negative symptoms. To explore this possibility, we examined the relationships between baseline metacognition and concurrent and prospective negative symptoms controlling for verbal memory. The participants were 62 adults diagnosed with serious mental illness enrolled in outpatient treatment. Metacognition was measured with the Metacognitive Assessment Scale-Abbreviated, symptoms were assessed using the Brief Psychiatric Rating Scale, and verbal memory was assessed using the California Verbal Learning Test. Significant correlations were found, indicating that poorer overall metacognition was associated with greater levels of negative symptoms assessed concurrently (r = 0.39) and 1 month later (r = 0.36). A significant relationship persisted after controlling for verbal memory and education. These findings support the idea that metacognitive deficits are related to negative symptoms and point to the potential of metacognitive interventions to positively influence negative symptoms.
Identifiants
pubmed: 32740145
doi: 10.1097/NMD.0000000000001219
pii: 00005053-202011000-00001
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
837-842Références
Ameen S, Ram D (2007) Negative symptoms in the remission phase of bipolar disorder. German J Psychiatry. 10:1–7.
Austin SF, Lysaker PH, Jansen JE, Trauelsen AM, Nielsen HGL, Pedersen MB, Haahr UH, Simonsen E (2019) Metacognitive capacity and negative symptoms in first episode psychosis: Evidence of a prospective relationship over a 3-year follow-up. J Exp Psychopathol. 10:1–11.
Blanchard JJ, Kring AM, Horan WP, Gur R (2011) Toward the next generation of negative symptom assessments: The collaboration to advance negative symptom assessment in schizophrenia. Schizophr Bull. 37:291–299.
Bleuler E (1950) Dementia praecox or the group of schizophrenias (J. Zinkin, Trans., published in 1911). New York, NY: International Universities Press, Inc.
Brady RO Jr., Gonsalvez I, Lee I, Öngür D, Seidman LJ, Schmahmann JD, Eack SM, Keshavan MS, Pascual-Leone A, Halko MA (2019) Cerebellar-prefrontal network connectivity and negative symptoms in schizophrenia. Am J Psychiatry. 176:512–520.
Buck KD, McLeod HJ, Gumley A, Dimaggio G, Buck BE, Minor K, James AV, Lysaker PH (2014) Anhedonia in prolonged schizophrenia spectrum patients with relatively lower vs. higher levels of depression disorders: Associations with deficits in social cognition and metacognition. Conscious Cogn. 10:68–75.
Cicero DC, Martin EA, Becker TM, Kerns JG (2016) Decreased self-concept clarity in people with schizophrenia. J Nerv Ment Dis. 204:142–147.
Cohen AS, McGovern JE, Dinzeo TJ, Covington MA (2014) Speech deficits in serious mental illness: A cognitive resource issue? Schizophr Res. 160:173–179.
Delis D, Kramer J, Kaplan E, Ober B (1987) The California Verbal Learning Test. New York, NY: Psychological Corporation.
Delis DC, Kramer JH, Kaplan E, Ober B (2000) CVLT-II, California Verbal Learning Test, Adult Version Manual. New York, NY: The Psychological Corporation.
Eack SM, Mesholam-Gately RI, Greenwald DP, Hogarty SS, Keshavan MS (2013) Negative symptom improvement during cognitive rehabilitation: Results from a 2-year trial of cognitive enhancement therapy. Psychiatry Res. 209:21–26.
First MB, Gibbon M, Spitzer RL, Williams JBW (2002) User's guide for the Structured Clinical Interview for DSM-IV-TR Axis I Disorders–Research Version–(SCID-I for DSM-IV-TR), November 2002 Revision. New York, NY: New York State Psychiatric Institute.
Fischer MW, Dimaggio G, Hochheiser J, Vohs JL, Phalen P, Lysaker PH (2020) Metacognitive capacity is related to self-reported social functioning and may moderate the effects of symptoms on interpersonal behavior. J Nerv Ment Dis. 208:138–142.
Fusar-Poli P, Papanastasiou E, Stahl D, Rocchetti M, Carpenter W, Shergill S, McGuire P (2015) Treatments of negative symptoms in schizophrenia: Meta-analysis of 168 randomized placebo-controlled trials. Schizophr Bull. 41:892–899.
García-Cabeza I, Díaz-Caneja CM, Ovejero M, de Portugal E (2018) Adherence, insight and disability in paranoid schizophrenia. Psychiatry Res. 270:274–280.
Gruber O, Santuccione Chadha A, Aach H (2014) Magnetic resonance imaging in studying schizophrenia, negative symptoms, and the glutamate system. Front Psych. 5:32.
Hamm JA, Buck B, Leonhardt BL, Wasmuth S, Lysaker JT, Lysaker PH (2017) Overcoming fragmentation in the treatment of persons with schizophrenia. J Theor Philos Psychol. 37:21–33.
Hamm JA, Renard SB, Fogley RL, Leonhardt BL, Dimaggio G, Buck KD, Lysaker PH (2012) Metacognition and social cognition in schizophrenia: Stability and relationship to concurrent and prospective symptom assessments. J Clin Psychol. 68:1303–1312.
Hasson-Ohayon I, Goldzweig G, Lavie A, Luther L, Lysaker PH (2018) The centrality of cognitive symptoms and metacognition within the interacting network of symptoms, neurocognition, social cognition and metacognition in schizophrenia. Schizophr Res. 202:260–266.
Hesse K, Kriston L, Wittorf A, Herrlich J, Wölwer W, Klingberg S (2015) Longitudinal relations between symptoms, neurocognition, and self-concept in schizophrenia. Front Psychol. 6:917.
Hochheiser J, Lundin LB, Lysaker PH (2019) The independent relationships of metacognition, mindfulness, and cognitive insight to self-compassion in schizophrenia. J Nerv Ment Dis. 208:1–6.
Hogarty GE, Flesher S (1999) Practice principles of cognitive enhancement therapy for schizophrenia. Schizophr Bull. 25:693–708.
Kaiser S, Lyne J, Agartz I, Clarke M, Morch-Johnson L, Faerden A (2017) Individual negative symptoms and domains—Relevance for assessment, pathomechanisms, and treatment. Schizophr Res. 186:39–45.
Kee KS, Horan WP, Salovey P, Kern RS, Sergi MJ, Fiske AP, Lee J, Subotnik KL, Nuechterlein K, Sugar CA, Green MF (2009) Emotional intelligence in schizophrenia. Schizophr Res. 107:61–68.
Lecomte T, Corbière M, Giguère C, Titone D, Lysaker P (2020) Group cognitive behaviour therapy for supported employment—Results of a randomized controlled cohort trial. Schizophr Res. 215:126–133.
Liu YC, Tang CC, Hung TT, Tsai PC, Lin MF (2018) The efficacy of metacognitive training for delusions in patients with schizophrenia: A meta-analysis of randomized controlled trials informs evidence-based practice. Worldviews Evid Based Nurs. 15:130–139.
Lukoff D, Liberman RP, Nuechterlein KH (1986) Symptom monitoring in the rehabilitation of schizophrenic patients. Schizophr Bull. 12:578–603.
Luther L, Firmin RL, Minor KS, Vohs JL, Buck B, Buck KD, Lysaker PH (2016b) Metacognition deficits as a risk factor for prospective motivation deficits in schizophrenia spectrum disorders. Psychiatry Res. 245:172–178.
Luther L, Firmin RL, Vohs JL, Buck KD, Rand KL, Lysaker PH (2016a) Intrinsic motivation as a mediator between metacognition deficits and impaired functioning in psychosis. Br J Clin Psychol. 55:332–347.
Lysaker PH, Carcione A, Dimaggio G, Johannesen JK, Nicolò G, Procacci M, Semerari A (2005) Metacognition amidst narratives of self and illness in schizophrenia: Associations with neurocognition, symptoms, insight and quality of life. Acta Psychiatr Scand. 112:64–71.
Lysaker PH, Klion R (2017) Recovery, meaning-making, and severe mental illness: A comprehensive guide to metacognitive reflection and insight therapy. New York, NY: Routledge.
Lysaker PH, Kukla M, Dubreucq J, Gumley A, McLeod H, Buck KD, Vohs J, Minor KM, Luther L, Leonhardt BL, Belanger EA, Popolo R, Dimaggio G (2015) Metacognitive deficits predict future levels of negative symptoms in schizophrenia controlling for neurocognition, affect recognition, and self-expectation of goal attainment. Schizophr Res. 168:267–272.
Lysaker PH, Minor KS, Lysaker JT, Hasson-Ohayon I, Bonfils K, Hochheiser J, Vohs JL (2019) Metacognitive function and fragmentation in schizophrenia: Relationship to cognition, self-experience and developing treatments. Schizophr Res Cogn. 19:100142.
Lysaker PH, Roe D, Yanos PT (2007) Toward understanding the insight paradox: Internalized stigma moderates the association between insight and social functioning, hope, and self-esteem among people with schizophrenia spectrum disorders. Schizophr Bull. 33:192–199.
Marder SR, Galderisi S (2017) The current conceptualization of negative symptoms in schizophrenia. World Psychiatry. 16:14–24.
McLeod HJ, Gumley AI, MacBeth A, Schwannauer M, Lysaker PH (2014) Metacognitive functioning predicts positive and negative symptoms over 12 months in first episode psychosis. J Psychiatr Res. 54:109–115.
Moritz S, Lysaker PH (2018) Metacognition—What did James H. Flavell really say and the implications for the conceptualization and design of metacognitive interventions. Schizophr Res. 201:20–26.
Moritz S, Veckenstedt R, Randjbar S, Vitzthum F, Woodward TS (2011) Antipsychotic treatment beyond antipsychotics: Metacognitive intervention for schizophrenia patients improves delusional symptoms. Psychol Med. 41:1823–1832.
Morrison AP, Pyle M, Chapman N, French P, Parker SK, Wells A (2014) Metacognitive therapy in people with a schizophrenia spectrum diagnosis and medication resistant symptoms: A feasibility study. J Behav Ther Exp Psychiatry. 45:280–284.
Orfanos S, Banks C, Priebe S (2015) Are group psychotherapeutic treatments effective for patients with schizophrenia? A systematic review and meta-analysis. Psychother Psychosom. 84:241–249.
Overall JE, Gorham DR (1962) The Brief Psychiatric Rating Scale. Psychol Reports. 1962:799–812.
Popolo R, MacBeth A, Canfora F, Rebecchi D, Toselli C, Salvatore G, Dimaggio G (2019) Metacognitive Interpersonal Therapy in Group (MIT-G) for young adults with personality disorders: A pilot randomized controlled trial. Psychol Psychother. 92:342–358.
Rector NA, Beck AT, Stolar N (2005) The negative symptoms of schizophrenia: A cognitive perspective. Can J Psychiatry. 50:247–257.
Sarkar S, Hillner K, Velligan DI (2015) Conceptualization and treatment of negative symptoms in schizophrenia. World J Psychiatry. 5:352–361.
Semerari A, Carcione A, Dimaggio G, Falcone M, Nicolo G, Procacci M, Alleva G (2003) How to evaluate metacognitive functioning in psychotherapy? The Metacognition Assessment Scale and its applications. Clin Psychol Psychother. 10:238–261.
Shafer A, Dazzi F, Ventura J (2017) Factor structure of the Brief Psychiatric Rating Scale–Expanded (BPRS-E) in a large hospitalized sample. J Psychiatr Res. 93:79–86.
Strassnig MT, Raykov T, O'Gorman C, Bowie CR, Sabbag S, Durand D, Patterson TL, Pinkham A, Penn DL, Harvey PD (2015) Determinants of different aspects of everyday outcome in schizophrenia: The roles of negative symptoms, cognition, and functional capacity. Schizophr Res. 165:76–82.
Strauss GP, Vertinski M, Vogel SJ, Ringdahl EN, Allen DN (2016) Negative symptoms in bipolar disorder and schizophrenia: A psychometric evaluation of the brief negative symptom scale across diagnostic categories. Schizophr Res. 170:285–289.
Sumiyoshi C, Sumiyoshi T, Nohara S, Yamashita I, Matsui M, Kurachi M, Niwa S (2005) Disorganization of semantic memory underlies alogia in schizophrenia: An analysis of verbal fluency performance in Japanese subjects. Schizophr Res. 74:91–100.
Trauelsen AM, Gumley A, Jansen JE, Pedersen MB, Nielsen HG, Trier CH, Haahr UH, Simonsen E (2016) Metacognition in first-episode psychosis and its association with positive and negative symptom profiles. Psychiatry Res. 238:14–23.
Winograd-Gurvich C, Fitzgerald PB, Georgiou-Karistianis N, Bradshaw JL, White OB (2006) Negative symptoms: A review of schizophrenia, melancholic depression and Parkinson's disease. Brain Res Bull. 70:312–321.
Wykes T (2019) Reflection in (and on) cognitive remediation. In Medalia A (Chair), Cognitive remediation in psychiatry. Talk presented at the meeting of 2019 Cognitive Remediation in Psychiatry Conference, New York, NY.